Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3

Molecular Cancer Research

Volumn 6, Issue 11, 2008, Pages 1755-1765

  Bharadwaj, Uddalak ^a   Li, Min ^a   Chen, Changyi ^a   Yao, Qizhi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN E; JANUS KINASE; MESOTHELIN; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; ENZYME INHIBITORS; GENE SILENCING; HUMANS; JANUS KINASES; MEMBRANE GLYCOPROTEINS; PANCREATIC NEOPLASMS; RNA, SMALL INTERFERING; S PHASE; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

AGOUTI PACA;

EID: 56449108335     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0095     Document Type: Article

References (47)

1. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
2. Chang K, Pai LH, Batra JK, Pastan I, Willingham MC. Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res 1992;52:181-6.
3. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majorityof ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker byserial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
4. Ho M, Bera TK, Willingham MC, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13:1571-5.
5. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
6. Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50.
7. Li M, Bharadwaj U, Zhang R, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7:286-96.
8. Adachi W, UlanovskyH, Li Y, et al. Serial analysis of gene expression (SAGE) in the rat limbal and central corneal epithelium. Invest Ophthalmol Vis Sci 2006;47:3801-10.
9. Uehara N, Unami A, Kiyozuka Y, et al. Parous mammary glands exhibit distinct alterations in gene expression and proliferation responsiveness to carcinogenic stimuli in Lewis rats. Oncol Rep 2006;15:903-11.
10. Cheng WF, Hung CF, Chai CY, et al. Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 2007;110:420-31.
11. Doree M, Galas S. The cyclin-dependent protein kinases and the control of cell division. FASEB J 1994;8:1114-21.
12. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol 1995;6:63-72.
13. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
14. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995;15:2672-81.
15. Hall M, Bates S, Peters G. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995;11:1581-8.
16. Roberts JM, Koff A, Polyak K, et al. Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol 1994;59:31-8.
17. Sanchez I, Dynlacht BD. Transcriptional control of the cell cycle. Curr Opin Cell Biol 1996;8:318-24.
18. Schneider G, Schmid RM. Genetic alterations in pancreatic carcinoma. Mol Cancer 2003;2:15.
19. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88.
20. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 1998;102:1385-92.
21. Ren Z, Schaefer TS. ErbB-2 activates Stat3 α in a Src- and JAK2-dependent manner. J Biol Chem 2002;277:38486-93.
22. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 bythe Src family kinase Hck requires a functional SH3 domain. J Biol Chem 2002;277:45680-7.
23. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-26.
24. Aggarwal BB, Sethi G, Ahn KS, et al. Targeting signal-transducer-and- activator-of-transcription-3 for prevention and therapyof cancer: modern target but ancient solution. Ann N Y Acad Sci 2006;1091:151-69.
25. Greten FR, Weber CK, Greten TF, et al. Stat3 and NF-κB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology2002;123:2052- 63.
26. Scholz A, Heinze S, Detjen KM, et al. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003;125:891-905.
27. DeArmond D, Brattain MG, Jessup JM, et al. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 2003;22:7781-95.
28. Toyonaga T, Nakano K, Nagano M, et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 2003;201:107-16.
29. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319-29.
30. Atherton-Fessler S, Liu F, Gabrielli B, et al. Cell cycle regulation of the p34cdc2 inhibitorykinases. Mol Biol Cell 1994;5:989-1001.
31. Norbury C, Nurse P. Cyclins and cell cycle control. Curr Biol 1991;1:23-4.
32. Hamburger AW, Salmon SE. Primarybioassay of human tumor stem cells. Science 1977;197:461-3.
33. Scholz CC, Berger DP, Winterhalter BR, Henss H, Fiebig HH. Correlation of drug response in patients and in the clonogenic assaywith solid human tumour xenografts. Eur J Cancer 1990;26:901-5.
34. Vogler M, Giagkousiklidis S, Genze F, et al. Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. Oncogene 2005;24:7190-202.
35. Skalicky DA, Kench JG, Segara D, et al. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1941-7.
36. Maitra A, AdsayNV , Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-12.
37. Iseki H, Ko TC, Xue XY, Seapan A, Townsend CM, Jr. A novel strategy for inhibiting growth of human pancreatic cancer cells byblocki ng cyclin-dependent kinase activity. J Gastrointest Surg 1998;2:36-43.
38. Kitahara K, Yasui W, Kuniyasu H, et al. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995;62:25-8.
39. Doucas H, Mann CD, Sutton CD, et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J Surg Oncol 2008;97:63-8.
40. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47.
41. Narimatsu M, Maeda H, Itoh S, et al. Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells. Mol Cell Biol 2001;21:6615-25.
42. Yeh HH, Lai WW, Chen HH, Liu HSSu WC. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006;25:4300-9.
43. Lang SA, Moser C, Gaumann A, et al. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1α autocrine loop, and reduces orthotopic tumor growth. Clin Cancer Res 2007;13:6459-68.
44. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
45. Sinibaldi D, Wharton W, Turkson J, et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000;19:5419-27.
46. Fuke H, Shiraki K, Sugimoto K, et al. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2007;363:738-44.
47. Lewis A, Du J, Liu J, et al. Metastatic progression of pancreatic cancer: changes in antioxidant enzymes and cell growth. Clin Exp Metastasis 2005;22:523-32.